NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: ICL, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations - Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions - IclLab.com
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations

 

NewswireTODAY - /newswire/ - Portland, OR, United States, 2024/05/03 - Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions - IclLab.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions.

Marked by a company-wide rebrand, ICL has shifted focus toward a broader spectrum of biotech pain points, ranging from supply chain consistency to atypical protein expression. New brand elements such as logos and colors have been added to the company’s website and social media presence, representing an aesthetic and procedural change toward the modernization of operations.

ICL has made several high impact staffing decisions, which have improved the reach of communications and the efficacy of collaboration. Research and development efforts have also increased at the company’s Portland headquarters, with plans in place to bolster offerings even further upon collaboration with affiliates.

“By investing more in R&D, we’re able to better support research that’s transforming the health outcomes for a thriving and resilient global community,” says ICL President John Leslie. “We're seeing the needs of the diagnostic industry evolve, and ICL aims to foster a culture of collaboration that drives innovation and empowers our customers and partners through this evolution.”

ICL was founded in 1977 by Gerrie Leslie, a notable figure in the industry for his contributions as the first scientist to characterize the IgY protein, commonly found in egg yolks. Since then, ICL has pioneered some of the industry's first commercialized immunoassay kits, such as ELISA kits designed to detect impurities in specific CHO host cell proteins.

About ICL

ICL (icllab.com) is a U.S.-based manufacturer of biochemical reagents and life science products. With over 45 years in the biotech industry, ICL has developed a strong presence among the world’s leading research institutions, in vitro diagnostics (IVD) manufacturers, and biopharma companies. Offering in-house research and development, ICL also provides custom solutions to research teams and IVD companies whose needs go beyond the industry standard.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: ICL, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ryan Negrini - IclLab.com 
503-747-2454 sales[.]icllab.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ICL, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ICL, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
SCHOTT Pharma Offers Complete Testing Suite for Container Selection and Drug Submission Preparation
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)